Pomalidomide

Generic Name
Pomalidomide
Brand Names
Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C13H11N3O4
CAS Number
19171-19-8
Unique Ingredient Identifier
D2UX06XLB5
Background

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Indication

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.

Associated Conditions
Kaposi's Sarcoma, Multiple Myeloma (MM)
Associated Therapies
-

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

First Posted Date
2015-09-07
Last Posted Date
2023-09-01
Lead Sponsor
Joseph Tuscano
Target Recruit Count
30
Registration Number
NCT02542657
Locations
🇺🇸

University of California Irvine, Orange, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

First Posted Date
2015-06-04
Last Posted Date
2018-09-13
Lead Sponsor
AbbVie
Target Recruit Count
74
Registration Number
NCT02462525
Locations
🇺🇸

Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States

🇺🇸

Mount Sinai Medical Center /ID# 133569, New York, New York, United States

🇺🇸

The University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States

and more 16 locations

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

First Posted Date
2015-04-30
Last Posted Date
2021-04-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
85
Registration Number
NCT02431208
Locations
🇺🇸

University of Maryland School of Medicine, Baltimore, Maryland, United States

🇺🇸

Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States

🇺🇸

Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States

and more 28 locations

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

First Posted Date
2015-04-14
Last Posted Date
2022-04-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
29
Registration Number
NCT02415153
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

🇺🇸

National Cancer Institute, Rockville, Maryland, United States

and more 9 locations

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2015-04-02
Last Posted Date
2024-12-05
Lead Sponsor
University of Leeds
Target Recruit Count
124
Registration Number
NCT02406222
Locations
🇬🇧

Beatson Oncology Centre, Glasgow, United Kingdom

🇬🇧

New Cross Hospital, Wolverhampton, United Kingdom

🇬🇧

Royal Sussex County Hospital, Brighton, United Kingdom

and more 18 locations

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

First Posted Date
2015-03-27
Last Posted Date
2024-07-09
Lead Sponsor
Celgene
Target Recruit Count
85
Registration Number
NCT02400242
Locations
🇺🇸

Gabrail Cancer Center Research, Canton, Ohio, United States

🇺🇸

University of Miami Medical Center, Miami, Florida, United States

🇺🇸

Local Institution - 104, Boston, Massachusetts, United States

and more 14 locations

Selinexor and Backbone Treatments of Multiple Myeloma Patients

First Posted Date
2015-01-21
Last Posted Date
2024-05-07
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
300
Registration Number
NCT02343042
Locations
🇺🇸

Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

First Posted Date
2014-11-19
Last Posted Date
2023-11-01
Lead Sponsor
Oncotherapeutics
Target Recruit Count
45
Registration Number
NCT02294357
Locations
🇺🇸

James R Berenson, MD, Inc., West Hollywood, California, United States

🇺🇸

Blood & Cancer Center of East Texas, Tyler, Texas, United States

🇺🇸

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

and more 4 locations

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

First Posted Date
2014-11-13
Last Posted Date
2019-11-05
Lead Sponsor
Ashraf Badros
Target Recruit Count
48
Registration Number
NCT02289222
Locations
🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

First Posted Date
2014-11-10
Last Posted Date
2020-07-15
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
9
Registration Number
NCT02287558
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath